This clinical trial is focused on studying the effects of a combined diuretic therapy on patients with chronic heart failure. Chronic heart failure is a condition where the heart is unable to pump blood effectively, leading to symptoms like shortness of breath and fatigue. The study will compare two treatment strategies. One group will receive the standard treatment with loop diuretics and potassium-sparing diuretics, which are medications that help remove excess fluid from the body. The other group will receive an experimental treatment that combines these standard medications with additional drugs called acetazolamide and metolazone. Acetazolamide and metolazone are also diuretics, but they work in different ways to help the body get rid of extra fluid.
The purpose of the study is to see if the combination of these medications can improve exercise capacity, help with breathing, and maintain a healthy fluid balance in the body better than the standard treatment alone. Participants in the study will take the medications in tablet form by mouth. The study will last for a period of three months, during which participants will be monitored to see how their condition responds to the treatment. The researchers aim to evaluate if the new combination therapy can reduce the number of times patients need to be hospitalized due to heart failure.
By participating in this study, researchers hope to gather valuable information that could lead to improved treatment options for people living with chronic heart failure. The study will help determine if the new combination of medications is more effective than the current standard treatment in managing the symptoms and complications associated with this condition.



Italy